Skip to main content

Advertisement

SpringerLink
Log in

The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Chondrosarcoma is a malignant bone tumor with poor prognosis. Surgical treatment is the first choice for chondrosarcomas. Chondrosarcoma is not sensitive to chemotherapy and radiotherapy. Identification of biological markers is important for the early diagnosis and targeted treatment of chondrosarcoma. This study investigated the protein expression and clinicopathological significance of ROR2 and FRAT1 in 59 chondrosarcomas and 33 osteochondromas.

Methods

ROR2 and FRAT1 protein expression in tissues was measured by immunohistochemistry.

Results

The percentage of positive ROR2 and FRAT1 expression was significantly higher in patients with chondrosarcoma than in patients with osteochondroma (P < 0.01). The percentage of positive ROR2 and FRAT1 expression was significantly lower in patients with histological grade I, AJCC stage I/II stage, Enneking stage I, non-metastatic and invasive chondrosarcoma than patients with histological grade III, AJCC stage III/IV, Enneking stage II + III, metastatic and invasive chondrosarcoma (P < 0.05 or P < 0.01). ROR2 expression was positively correlated with FRAT1 expression in chondrosarcoma. Kaplan–Meier survival analysis demonstrated that histological grade, AJCC stage, Enneking stage, metastasis, invasion, and ROR2 and FRAT1 expression significantly correlated with a short mean survival time of patients with chondrosarcoma (P < 0.05 or P < 0.01). Cox multivariate analysis showed that positive ROR2 and FRAT1 expression was an independent prognostic factor that negatively correlated with postoperative survival and positively correlated with mortality.

Conclusion

Positive ROR2 and FRAT1 expression is associated with the progression and poor prognosis of chondrosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pritchard DJ, Lunke RJ, Taylor WF, Dahlin DC, Medley BE. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer. 1980;45:149–57.

    Article  CAS  PubMed  Google Scholar 

  2. Sekharappa V, Amritanand R, Krishnan V, David KS. Symptomatic solitary osteochondroma of the subaxial cervical spine in a 52-year-old patient. Asian Spine J. 2014;8:84–8.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Kim MJ, Cho KJ, Ayala AG, Ro JY. Chondrosarcoma: with updates on molecular genetics. Sarcoma. 2011;2011:405437.

    PubMed Central  PubMed  Google Scholar 

  4. Ford CE, Qian Ma SS, Quadir A, Ward RL. The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer. 2013;133:779–87.

    Article  CAS  PubMed  Google Scholar 

  5. Niehrs C. The complex world of WNT receptor signaling. Nat Rev Mol Cell Biol. 2012;13:767–79.

    Article  CAS  PubMed  Google Scholar 

  6. Ren D, Minami Y, Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following snail-mediated epithelial-mesenchymal transition. Genes Cells. 2011;16:304–15.

    Article  CAS  PubMed  Google Scholar 

  7. Saitoh T, Mine T, Katoh M. Molecular cloning and expression of proto-oncogene FRAT1 in human cancer. Int J Oncol. 2002;20:785–9.

    CAS  PubMed  Google Scholar 

  8. van Amerongen R, Nawijn MC, Lambooij JP, Proost N, Jonkers J, Berns A. Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways. Oncogene. 2010;29:93–104.

    Article  PubMed  Google Scholar 

  9. Heymann D, Rédini F. Targeted therapies for bone sarcomas. Bonekey Rep. 2013;2:378.

    Article  PubMed Central  PubMed  Google Scholar 

  10. O’Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29:34–44.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, et al. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene. 2009;28:2513–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Katoh Y, Katoh M. Comparative integromics on FAT1, FAT2, FAT3 and FAT4. Int J Mol Med. 2006;18:523–8.

    CAS  PubMed  Google Scholar 

  13. Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 2012;227:223–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Lu BJ, Wang YQ, Wei XJ, Rong LQ, Wei D, Yan CM, et al. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Rep. 2012;5:1033–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100:1227–33.

    Article  CAS  PubMed  Google Scholar 

  16. Lara E, Calvanese V, Huidobro C, Fernández AF, Moncada-Pazos A, Obaya AJ, et al. Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer. 2010;9:170.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Geng M, Cao YC, Chen YJ, Jiang H, Bi LQ, Liu XH. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol. 2012;18:1328–38.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grandér D, et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma. 2013;54:843–50.

    Article  CAS  PubMed  Google Scholar 

  19. Endo M, Doi R, Nishita M, Minami Y. Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex. Cell Sci. 2012;125:2017–29.

    Article  CAS  Google Scholar 

  20. Al-Shawi R, Ashton SV, Underwood C, Simons JP. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev Genes Evol. 2001;211:161–71.

    Article  CAS  PubMed  Google Scholar 

  21. Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int J Oncol. 2001;19:311–5.

    CAS  PubMed  Google Scholar 

  22. van Amerongen R, Nawijn M, Franca-Koh J, Zevenhoven J, van der Gulden H, Jonkers J, et al. Frat is dispensable for canonical Wnt signaling in mammals. Genes Dev. 2005;19:425–30.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Wang Y, Liu S, Zhu H, Zhang W, Zhang G, Zhou X, et al. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int J Cancer. 2008;123:561–8.

    Article  CAS  PubMed  Google Scholar 

  24. Zhang Y, Han Y, Zheng R, Yu JH, Miao Y, Wang L, et al. Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC. Tumour Biol. 2012;33:1437–44.

    Article  CAS  PubMed  Google Scholar 

  25. Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H, Zhou C, et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer. 2006;94:686–91.

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Guo G, Mao X, Wang P, Liu B, Zhang X, Jiang X, et al. The expression profile of FRAT1 in human gliomas. Brain Res. 2010;1320:152–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Central South University’s fund for independent exploration and innovation of Graduate (No.: 2013zzts336).

Conflict of interest

All authors declared no any conflict of interest.

Author information

Authors and Affiliations

  1. Department of Orthopedics, Second Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China

    L. He & W. Wang

  2. Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People’s Republic of China

    Z. Yang

  3. Department of Pathology, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    J. Zhou

Authors
  1. L. He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, L., Yang, Z., Zhou, J. et al. The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors. Clin Transl Oncol 17, 438–445 (2015). https://doi.org/10.1007/s12094-014-1254-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1254-y

Keywords

Search

Navigation